Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.
Rhythm Pharmaceuticals
NASDAQ: RYTM $105.02 USD
Commercial-stage rare disease biopharmaceutical company focused on melanocortin-4 receptor (MC4R) pathway therapeutics; lead product IMCIVREE (setmelanotide) treats hyperphagia and severe obesity caused by POMC, PCSK1, LEPR and Bardet-Biedl syndrome deficiencies.
Company Info
Sector:Biotechnology — Rare Disease Therapeutics
Headquarters:Boston, Massachusetts, USA
Founded:2008
Website:rhythmtx.com/
Clinical Development Pipeline
setmelanotide (IMCIVREE)
Target: MC4Rsetmelanotide (IMCIVREE)
Target: MC4Rbivamelagon (LB54640)
Target: MC4RRecent News
Leadership Team
David Meeker
Chairman, President and Chief Executive Officer
Hunter Smith
Chief Financial Officer